Teva’s New Copaxone Gaining Market Share Ahead Of Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
With the imminent possibility of generic competition to Copaxone, Teva looks to move 65% of current patients to its thrice-weekly version by the end of 2014.